UCBJY Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 апр. 2024 @ 22:45):

Stats
Объем за сегодня	36 599.00
Средний объем	12 804.00
Рыночная капитализация	25.23B
Last Dividend	$0.726 ( 2023-05-01 )
Next Dividend	$0 ( N/A )
P/E	70.72
ATR14	$0.189 (0.28%)

UCB SA Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

UCB SA Финансовые показатели

Annual	2023
Выручка:	$5.25B
Валовая прибыль:	$3.55B (67.50 %)
EPS:	$1.810

FY	2023
Выручка:	$5.25B
Валовая прибыль:	$3.55B (67.50 %)
EPS:	$1.810

FY	2022
Выручка:	$5.52B
Валовая прибыль:	$3.84B (69.64 %)
EPS:	$2.20

FY	2021
Выручка:	$5.78B
Валовая прибыль:	$4.34B (75.11 %)
EPS:	$5.60

Financial Reports:

No articles found.

UCB SA Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0.726 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

UCB SA Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.90 - Stable (2.00%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.663	2013-05-02
Last Dividend	$0.726	2023-05-01
Next Dividend	$0	N/A
Payout Date	2023-05-18
Next Payout Date	N/A
# dividends	11	--
Total Paid Out	$7.46	--
Avg. Dividend % Per Year	0.00%	--
Score	3.23	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.90
Div. Directional Score	8.72	--

Next Divdend (Est)
(2025-03-31)

$0.745 Estimate 3.11 %

Dividend Stability

0.25 Very Poor

Dividend Score

3.23

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
OLCLF	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%
DELKY	Ex Dividend Knight	2023-09-01	Quarterly	0.00%
TRBK	Ex Dividend Junior	2023-08-03	Semi-Annually	0.00%
ITJTY	Ex Dividend Junior	2023-10-31	Annually	0.00%
BKKPF	Ex Dividend Junior	2023-09-06	Annually	0.00%
PUODY	Ex Dividend Knight	2023-06-21	Annually	0.00%
EPOKY	Ex Dividend Knight	2023-10-23	Semi-Annually	0.00%
VDMCY	Ex Dividend Knight	2023-06-22	Semi-Annually	0.00%
KSBI	Ex Dividend Knight	2023-07-28	Quarterly	0.00%
CGEMY	Ex Dividend Knight	2023-05-25	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0656	1.500	8.69	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0331	1.200	8.90	10.00	[0 - 0.3]
returnOnEquityTTM	0.0571	1.500	-0.477	-0.715	[0.1 - 1]
payoutRatioTTM	0.490	-1.000	5.10	-5.10	[0 - 1]
currentRatioTTM	1.317	0.800	8.42	6.73	[1 - 3]
quickRatioTTM	0.839	0.800	9.77	7.81	[0.8 - 2.5]
cashRatioTTM	0.329	1.500	9.28	10.00	[0.2 - 2]
debtRatioTTM	0.196	-1.500	6.74	-10.00	[0 - 0.6]
interestCoverageTTM	4.50	1.000	9.45	9.45	[3 - 30]
operatingCashFlowPerShareTTM	5.26	2.00	8.25	10.00	[0 - 30]
freeCashFlowPerShareTTM	2.96	2.00	8.52	10.00	[0 - 20]
debtEquityRatioTTM	0.338	-1.500	8.65	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.648	1.000	2.54	2.54	[0.2 - 0.8]
operatingProfitMarginTTM	0.120	1.000	9.59	9.59	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.328	1.000	9.29	9.29	[0.2 - 2]
assetTurnoverTTM	0.505	0.800	9.97	7.97	[0.5 - 2]
Total Score				12.54

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	22.86	1.000	7.79	0	[1 - 100]
returnOnEquityTTM	0.0571	2.50	-0.306	-0.715	[0.1 - 1.5]
freeCashFlowPerShareTTM	2.96	2.00	9.01	10.00	[0 - 30]
dividendYielPercentageTTM	2.34	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	5.26	2.00	8.25	10.00	[0 - 30]
payoutRatioTTM	0.490	1.500	5.10	-5.10	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.127	1.000	9.32	0	[0.1 - 0.5]
Total Score				4.90

UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.